U.S. Health Care REITs Stock News

Globus Medical (GMED) has just wrapped up FY 2025 with fourth quarter revenue of US$826.4 million and basic EPS of US$1.05, against a backdrop of trailing twelve month EPS of US$3.98 supported by net income of US$537.9 million. The company has seen revenue move from US$657.3 million in Q4 2024 to US$826.4 million in Q4 2025. Trailing net margin sits at 18.3% compared with 4.1% a year earlier, giving a clearer view of how sales and EPS are feeding through to profitability. Taken together with...

Clean Energy Fuels (CLNE) has closed out FY 2025 with fourth quarter revenue of US$112.3 million and a basic EPS loss of US$0.20, alongside a trailing twelve month revenue base of US$424.8 million and a loss of US$1.01 per share. Over recent quarters, the company has seen revenue move from US$103.8 million in Q1 2025 to US$112.3 million in Q4 2025, while quarterly basic EPS losses have ranged from US$0.60 in Q1 2025 to US$0.20 in Q4 2025, keeping margins in negative territory and highlighting...

Ginkgo Bioworks Holdings (DNA) has wrapped up FY 2025 with fourth quarter revenue of about US$33.4 million and a basic EPS loss of US$1.41, alongside a net income loss of US$80.8 million. The company has seen trailing twelve month revenue move from US$227.0 million in Q4 2024 to US$170.2 million in Q4 2025. Over the same period, trailing EPS has shifted from a loss of US$10.54 to a loss of US$5.64, indicating that the business is still absorbing heavy costs even as losses on a per share basis...

Liberty Latin America (LILA) has just wrapped up FY 2025 with Q4 revenue of US$1,159.5 million and a basic EPS loss of US$0.27, while trailing twelve month revenue came in at US$4.4 billion with a basic EPS loss of US$3.06. Over recent quarters, revenue has ranged from US$1,083.5 million in Q1 2025 to US$1,159.5 million in Q4 2025, as EPS has moved between a loss of US$2.12 in Q2 2025 and a small profit of US$0.02 in Q3 2025, highlighting that earnings remain volatile even on a multi quarter...

ICF International (ICFI) closed FY 2025 with fourth quarter revenue of US$443.7 million and basic EPS of US$0.94, while trailing 12 month revenue was US$1.9 billion and EPS reached US$4.97. Over the last six reported quarters, the company has seen quarterly revenue move from US$517.0 million in Q3 2024 to US$443.7 million in Q4 2025, with basic EPS ranging from US$1.74 in Q3 2024 to US$0.94 most recently. With trailing net profit margins in the mid single digits and earnings forecasts...

RE/MAX Holdings (RMAX) has just wrapped up FY 2025 with fourth quarter revenue of US$71.1 million and basic EPS of US$0.07, against a backdrop of trailing twelve month revenue of US$291.6 million and EPS of US$0.41 that was linked with 14.5% earnings growth year over year and a net margin of 2.8% versus 2.3% a year earlier. Over recent quarters, the company has seen quarterly revenue move between US$71.1 million and US$74.5 million while basic EPS ranged from a loss of US$0.10 in Q1 2025 to...

Fastly (NasdaqGS:FSLY) reported robust first quarter results with 20% year over year revenue growth. The company’s security business recorded 47% revenue growth, supported by new AI driven security products. Despite the operational performance and product launches, Fastly’s share price fell over 35% after the results as investor expectations exceeded the upgraded outlook. Fastly operates as an edge cloud and security platform, helping customers deliver and protect digital experiences closer...

PRA Group’s FY 2025 earnings in focus PRA Group (PRAA) closed FY 2025 with fourth quarter revenue of US$333.4 million and EPS of US$1.46, setting the tone for how investors may reframe the story around profitability and margins. Over recent quarters, the company reported revenue of US$269.6 million in Q1 2025 and US$333.4 million in Q4 2025, while quarterly EPS ranged from US$0.09 in Q1 2025 to US$1.46 in Q4 2025 and included a loss of US$10.43 in Q3 2025. With trailing 12 month results still...

ICU Medical (ICUI) has wrapped up FY 2025 with fourth quarter revenue of US$540.7 million and a basic EPS loss of US$0.64, while trailing twelve month revenue sits at about US$2.2 billion with basic EPS of roughly US$0.03 and net income of about US$0.7 million. Over the past six quarters, revenue has ranged from US$536.99 million to US$629.81 million and quarterly basic EPS has swung between a loss of US$1.35 and a profit of US$1.43, underscoring how sensitive margins have been to shifts in...

MercadoLibre (MELI) just closed FY 2025 with fourth quarter revenue of US$8.8b and basic EPS of US$11.03, alongside full year trailing twelve month revenue of US$28.9b and EPS of US$39.39. Over recent periods the company has seen quarterly revenue move from US$6.1b and EPS of US$12.60 in Q4 2024 to US$7.4b and EPS of US$8.30 in Q3 2025, before reaching the latest Q4 2025 levels. This sets up a results season where investors are focused on how margin trends balance against the headline growth...

Kimbell Royalty Partners (KRP) has just wrapped up FY 2025 with Q4 revenue of US$77.1 million and basic EPS of US$0.21, supported by trailing twelve month revenue of US$321.7 million and EPS of US$0.62. Over recent periods the company has seen quarterly revenue move between US$70.9 million and US$90.3 million, while basic EPS has ranged from a loss of US$0.48 to a profit of US$0.22, giving investors a mixed but data rich backdrop for assessing earnings quality. With trailing results pointing...

GCM Grosvenor (GCMG) has wrapped up FY 2025 with fourth quarter revenue of US$176.4 million and basic EPS of US$0.33, alongside trailing 12 month EPS of US$0.87 on revenue of US$554.4 million and earnings growth of 142.7% over the past year. Over the last few quarters, revenue has moved from US$165.1 million in Q4 FY 2024 to US$176.4 million in Q4 FY 2025, while quarterly EPS shifted from US$0.17 to US$0.33 over the same period. This was backed by a trailing 12 month net profit margin of 8.2%...

If you are wondering whether OneMain Holdings at around US$55.69 is offering genuine value or just looks cheap on the surface, this article will help you size up the stock through a valuation lens. The share price has seen mixed moves recently, with a 5.2% decline over the last week, a 3.5% gain over the past month, and a 19.4% decline year to date. Over longer periods, the 1 year and 3 year returns of 20.1% and 96.9% sit alongside a 64.5% return over 5 years. Recent headlines around OneMain...

Amneal Pharmaceuticals (AMRX) has closed out FY 2025 with fourth quarter revenue of US$814.3 million and basic EPS of US$0.11, alongside trailing twelve month revenue of about US$3.0 billion and basic EPS of US$0.23. Over recent periods the company has seen quarterly revenue move from US$702.5 million in Q3 FY 2024 to US$730.5 million in Q4 FY 2024 and then to US$695.4 million, US$724.5 million, US$784.5 million and US$814.3 million across the four quarters of FY 2025. Basic EPS shifted from...

Nelnet (NNI) has capped FY 2025 with fourth quarter total revenue of US$341.5 million and basic EPS of US$1.60, alongside trailing 12 month revenue of US$1.7 billion and EPS of US$11.79, set against a one year earnings growth figure of 132.8%. Over recent periods, total revenue has moved from US$373.5 million and EPS of US$1.73 in Q4 FY 2024 to US$516.1 million with EPS of US$4.97 in Q2 FY 2025 and US$435.7 million with EPS of US$2.94 in Q3 FY 2025, illustrating a year in which shifting...

Wondering whether Maase at US$9.30 is priced for opportunity or already reflecting expectations? This article walks through what the current valuation suggests about the stock. Over the last month, the share price return of 64.0% and a year-to-date return of 59.7%, despite a 4.1% decline over the past week, indicate that the market's view on the stock has been shifting quickly. Recent coverage around Maase has focused on its positioning within the insurance sector and how investors are...

TeraWulf FY 2025: Headline Numbers and What They Signal TeraWulf (WULF) has reported FY 2025 results with fourth quarter revenue of US$35.8 million and a basic EPS loss of US$0.30, alongside net income excluding extra items of a US$126.6 million loss. This sets the tone for a year where scale and profitability are clearly still in tension. Over recent quarters, the company has seen revenue move from US$27.1 million in Q3 2024 to US$34.4 million in Q1 2025, US$47.6 million in Q2 2025, US$50.6...

Q1 2026 earnings snapshot Lee Enterprises (LEE) opened fiscal 2026 with Q1 revenue of $130.1 million and a basic EPS loss of $0.92, alongside trailing twelve month revenue of $547.8 million and a basic EPS loss of $4.34. Over recent quarters the company has seen revenue move from $144.6 million in Q1 2025 to $130.1 million in Q1 2026. Quarterly basic EPS has ranged from a loss of $2.80 to a loss of $0.31 as net income excluding extra items moved between a loss of $16.7 million and a loss of...

Oshkosh (OSK) just wrapped up FY 2025 with Q4 revenue of US$2,688.8 million and basic EPS of US$2.11, supported by trailing twelve month revenue of US$10.4 billion and EPS of US$10.08. The company has seen quarterly revenue move from US$2,598.1 million in Q4 2024 to US$2,688.8 million in Q4 2025, while quarterly EPS shifted from US$2.35 to US$2.11 over the same period. This sets up a picture of steady scale with earnings that investors will be dissecting closely. With a trailing net margin of...

Xponential Fitness (XPOF) closed out FY 2025 with Q4 revenue of US$83.0 million and a basic EPS loss of US$1.17, alongside a trailing twelve month revenue base of US$314.9 million and a TTM basic EPS loss of US$1.47. Over the last six reported quarters, the company has seen quarterly revenue range from US$76.2 million to US$83.2 million while basic EPS losses have moved between US$0.01 and US$1.36. This gives investors a clearer view of how sales and per share results have interacted through...

Forward Air (FWRD) just posted its FY 2025 fourth quarter results with revenue of US$631.2 million and a basic EPS loss of US$0.91, while trailing twelve month revenue stands at US$2.5 billion against a trailing EPS loss of US$3.51 and a net loss of US$107.8 million. Over recent quarters, the company has seen quarterly revenue hold in a tight range around US$613.3 million to US$655.9 million, while quarterly EPS losses have moved between US$0.41 and US$2.59. This gives investors a clear view...

Wendy's (WEN) just closed FY 2025 with fourth quarter revenue of US$543 million and basic EPS of US$0.14, alongside net income of US$26 million. Trailing twelve month revenue stood at about US$2.2 billion with EPS of US$0.85. Over recent quarters the company has seen quarterly revenue move from US$523 million in Q1 2025 to US$561 million in Q2 and US$550 million in Q3, with quarterly EPS ranging between US$0.20 and US$0.29 across the first three quarters. This sets up a picture where solid...

BridgeBio Pharma (BBIO) closed out FY 2025 with Q4 revenue of US$154.2 million and a basic EPS loss of US$0.99, while trailing 12 month revenue stood at US$502.1 million and EPS at a loss of US$3.78. Over the past six quarters, the company has seen quarterly revenue move from US$2.7 million in Q3 2024 to US$154.2 million in Q4 2025, with basic EPS losses ranging between US$0.86 and US$1.40 over that span. This sets a clear backdrop of high revenue levels paired with ongoing losses. For...

Crinetics Pharmaceuticals (CRNX) closed out FY 2025 with Q4 revenue of US$6.2 million and a basic EPS loss of US$1.29, alongside a net loss of US$122.8 million. Trailing 12 month figures show revenue of US$7.7 million and a basic EPS loss of US$4.95 on a net loss of US$465.3 million. The company’s quarterly revenue moved from US$0 in Q3 2024 to US$6.2 million in Q4 2025, while EPS losses widened from US$0.96 to US$1.29 over the same span, which keeps attention on how quickly revenue can scale...